BRAF and neoplasm: Compared with patients who had detectable BRAF-V600E by ctDNA genomic profiling, those who had undetectable BRAF-V600E had smaller baseline tumor sizes (median (interquartile range; IQR) 40.00 mm (28.00–72.00) versus 66.00 mm (42.00–97.00); P = 0.001) and lower baseline ctDNA maximum variant allele frequency (maxVAF) (0.830% (0.350–4.200) versus 13.605% (2.595–35.680); P < 0.0001) (Fig. 2b).